Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women of childbearing potential must agree to use an acceptable method of birth control~* clinical diagnosis of community acquired bacterial pneumonia (CABP)~* PORT score of II or greater~* able to generate an adequate sputum specimen~* chest x-ray showing presence of new infiltrates in a lobar or multilobar distribution characteristic of bacterial pneumonia~Exclusion Criteria:~* history of tendon damage/disorders due to quinolone therapy~* uncorrected hypokalemia~* history of myasthenia gravis~* intubated at the time of consent OR subject is a candidate for enrollment into the open-label S. aureus arm and has been intubated greater than 12 hours prior to randomization~* mild CABP with a PORT score of less than II~* viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis~* pneumonia suspected to be secondary to aspiration~* primary, solitary lung abscess~* healthcare-associated pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia~* known bronchial obstruction or a history of postobstructive pneumonia.~* primary lung cancer or another malignancy metastatic to the lungs~* cystic fibrosis, known or suspected Pneumocystis jiroveci (carinii) pneumonia, or known or suspected active tuberculosis~* infection that necessitates the use of a concomitant antibacterial agent in addition to study medication~* systemic antibiotics within the last 96 hours before randomization, with exceptions~* hospitalized for greater than 72 hours for any reason 30 days before randomization (excluding the 24 hour period before enrollment).~* history of a serious hypersensitivity reaction to any quinolone including moxifloxacin.~* female and pregnant, breastfeeding, or may be pregnant.~Other protocol-specific eligibility criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-32729463 (Type: EXPERIMENTAL): None
- moxifloxacin (Type: ACTIVE_COMPARATOR): None
- JNJ-32729463 Open-Label (Type: EXPERIMENTAL): subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites

Based on this trial design, predict the completion outcome and termination type (if applicable).